CNSP vs. BLRX, AYTU, BIVI, CGTX, JATT, QTTB, LPCN, CING, MTEX, and GELS
Should you be buying CNS Pharmaceuticals stock or one of its competitors? The main competitors of CNS Pharmaceuticals include BioLineRx (BLRX), Aytu BioPharma (AYTU), BioVie (BIVI), Cognition Therapeutics (CGTX), JATT Acquisition (JATT), Q32 Bio (QTTB), Lipocine (LPCN), Cingulate (CING), Mannatech (MTEX), and Gelteq (GELS). These companies are all part of the "pharmaceutical products" industry.
CNS Pharmaceuticals vs. Its Competitors
CNS Pharmaceuticals (NASDAQ:CNSP) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.
14.0% of CNS Pharmaceuticals shares are held by institutional investors. Comparatively, 1.6% of BioLineRx shares are held by institutional investors. 0.1% of CNS Pharmaceuticals shares are held by company insiders. Comparatively, 1.1% of BioLineRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
CNS Pharmaceuticals currently has a consensus target price of $25.00, indicating a potential upside of 2,599.78%. BioLineRx has a consensus target price of $26.00, indicating a potential upside of 481.66%. Given CNS Pharmaceuticals' higher probable upside, equities analysts plainly believe CNS Pharmaceuticals is more favorable than BioLineRx.
CNS Pharmaceuticals has a beta of 2.58, meaning that its share price is 158% more volatile than the S&P 500. Comparatively, BioLineRx has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500.
BioLineRx has higher revenue and earnings than CNS Pharmaceuticals. BioLineRx is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, BioLineRx had 2 more articles in the media than CNS Pharmaceuticals. MarketBeat recorded 3 mentions for BioLineRx and 1 mentions for CNS Pharmaceuticals. CNS Pharmaceuticals' average media sentiment score of 0.75 beat BioLineRx's score of 0.22 indicating that CNS Pharmaceuticals is being referred to more favorably in the media.
CNS Pharmaceuticals has a net margin of 0.00% compared to BioLineRx's net margin of -15.21%. BioLineRx's return on equity of -23.93% beat CNS Pharmaceuticals' return on equity.
Summary
BioLineRx beats CNS Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
Get CNS Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNSP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CNSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CNS Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:CNSP) was last updated on 7/9/2025 by MarketBeat.com Staff
